MEHTA API

MEHTA API, established in 1970, is an Indian pharmaceutical manufacturer with a strong active-ingredient patent and regulatory portfolio, holding patents on Aprepitant, Erythromycin, and Agomelatine. Since setting up dedicated small- and medium-volume API facilities in 2011 and a high-potency API block for Prostaglandin in 2013, the company has secured CEP certifications for Erythromycin, Bisoprolol Fumarate, and Rivaroxaban, DMF approvals across multiple European and Asian regulatory bodies (including PMDA Japan and CDE China), and EU-GMP approval for five-plus products, most recently expanding capacity for high-potency and oncology APIs in 2023-2024. Offering CMO contract manufacturing under its own brand with international approvals, an experienced R&D staff, and a large product line, the company accommodates buyer specifications and small orders, serving markets across Central/South America, Western and Eastern Europe, Asia, the Middle East, and Africa.